The center ring at ASCO this weekend will feature CTL019, Novartis’ lead CAR-T that appears to be headed to a landmark approval in a matter of months. But the pharma giant will also be putting the spotlight on a next-gen CAR-T therapy — CTL119 — with a compelling glimpse at its promise of improving reengineered cells’ persistence, amping up their therapeutic potential.
This new model CAR is made with a humanized CAR protein with, presumably, greater affinity to human proteins than the mouse proteins used in the first wave of CARs built at the University of Pennsylvania.
In a small study to be reviewed at ASCO, investigators added the drug to Imbruvica (ibrutinib) among 9 patients with treatment-resistant chronic lymphocytic leukemia that had not been beaten into remission. All 9 had been on ibrutinib for at least six months prior to adding CD19-targeting CTL119 to their treatment regimen.
After three months, 8 of 9 evaluable patients were free of any sign of cancer in their bone marrow. The 9th had a partial response.
The work at Novartis reflects a commitment from all the lead players that the first wave of CAR-Ts — including KTE-C19 (axicabtagene ciloleucel) from Kite Pharmaceuticals — can be improved on with new technology. But it’s even more important for Novartis, which is out to demonstrate that it is completely committed to developing novel waves of CAR-Ts.
Novartis made one of the biggest splashes when it jumped into CAR-T — reengineering patients’ immune cells to attack cancer cells — with Carl June and his colleagues at Penn. And the Big Pharma player stunned the oncology field last summer when it abruptly shredded a separate cell and gene therapy unit — laying off more than 100 and reintegrating the work back into the broader R&D organization. To many, including members of its own team, that move —followed by a recent defection in the new team in charge of CAR-T — looked like a retreat amid considerable disarray.
By focusing on new constructs and new deals, Novartis execs are signaling that they plan to remain a dominant player. And CTL119 is part of that case.
Said James Bradner, president of the Novartis Institutes for BioMedical Research:
CTL119 represents one of our latest advances in CAR-T cell therapy research and our broader commitment to pioneering breakthrough immuno-oncology treatments.
The underlying message: Novartis is planning to stay a leader long after CTL019 makes drug history.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.Free Subscription